|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM333967151 |
| 003 |
DE-627 |
| 005 |
20231225222732.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202106307
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1113.xml
|
| 035 |
|
|
|a (DE-627)NLM333967151
|
| 035 |
|
|
|a (NLM)34859919
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Pan, Jingmei
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Self-Blockade of PD-L1 with Bacteria-Derived Outer-Membrane Vesicle for Enhanced Cancer Immunotherapy
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.03.2022
|
| 500 |
|
|
|a Date Revised 14.07.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The checkpoint inhibitor therapy that blocks programmed death-1 (PD-1) and its major ligand PD-L1 has achieved encouraging clinical efficacy in certain cancers. However, the binding of checkpoint inhibitors with other immune cells that express PD-L1 often results in a low response rate to the blockade and severe adverse effects. Herein, an LyP1 polypeptide-modified outer-membrane vesicle (LOMV) loaded with a PD-1 plasmid is developed to achieve self-blockade of PD-L1 in tumor cells. The nanocarriers accumulate in the tumor tissue through OMV-targeting ability and are internalized into the tumor cells via the LyP1-mediated target, subsequently delivering PD-1 plasmid into the nucleus, leading to the expression of PD-1 by the tumor cells. In addition, a magnetic particle chemiluminescence kit is developed to quantitatively detect the binding rate of PD-1/PD-L1. The self-expressed PD-1 bonded with the PD-L1 is expressed by both autologous and neighboring tumor cells, achieving self-blockade. Simultaneously, the outer-membrane protein of LOMV recruits cytotoxic lymphocyte cells and natural killer cells to tumor tissues and stimulates them to secrete IFN-γ , improving the antitumor activity of the PD-1/PD-L1 self-blocking therapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a immune checkpoint
|
| 650 |
|
4 |
|a immune response
|
| 650 |
|
4 |
|a immunotherapy
|
| 650 |
|
4 |
|a nanocarriers
|
| 650 |
|
4 |
|a outer-membrane vesicles
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD274 protein, human
|2 NLM
|
| 700 |
1 |
|
|a Li, Xilin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shao, Binfen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Funeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Xuehui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guo, Xing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Shaobing
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 7 vom: 27. Feb., Seite e2106307
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:7
|g day:27
|g month:02
|g pages:e2106307
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202106307
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 7
|b 27
|c 02
|h e2106307
|